Brain Biotech Ag · XETR:BNN

Brain Biotech — Investor Day (February 2023)

10 slides from Brain Biotech's investor day presentation, Feb 27, 2023

  1. Slide 1: BRAIN Biotech AG Capital Markets Day 2023

    BRAIN Biotech AG Creating a #BiobasedFuture Capital Markets Day 2023 Zwingenberg, February 27, 2023 Since 2021 we have been committed to the UN Global Compact corporate responsibility initiative and its principles in the areas of human rights, labor, the environment and anti-corruption. Creating a #

  2. Slide 2: Efficient & Transparent Organization: Performance Made Visible

    Capital Markets Day 2023 Creating a #BiobasedFuture Efficient & Transparent Organization: Performance Made Visible Michael Schneiders, CFO Creating a #BiobasedFuture © BRAIN Biotech AG Zwingenberg Germany www.brain-biotech.com +49 (0) 6251-9331-0 22

  3. Slide 3: Efficient & Transparent Organization: aligning external reporting with business accountability

    Efficient & Transparent Organization aligning external reporting with business accountability BRAIN Biotech AG Creating a #BiobasedFuture Holding Costs ~€3.0m BioProducts BioScience BioIncubator Application Based Fermentation & Formulation Bespoke Customer Solutions Building the Future in Biotech En

  4. Slide 4: Harvesting clearly defined synergies within the group, sustainability embedded

    Efficient & Transparent Organization harvesting clearly defined synergies within the group, sustainability embedded BRAIN Biotech AG Creating a #BiobasedFuture BioProducts BioScience BioIncubator Application Based Fermentation & Formulation Bespoke Customer Solutions Building the Future in Biotech F

  5. Slide 5: Clear management accountability

    Efficient & Transparent Organization clear management accountability BRAIN Biotech AG Creating a #BiobasedFuture Adriaan Moelker Michael Schneiders Group CEO Group CFO BioProducts BioScience BioIncubator Application Based Fermentation & Formulation Bespoke Customer Solutions Building the Future in B

  6. Slide 6: Significantly reducing complexity

    Efficient & Transparent Organization significantly reducing complexity Today • 17 entities • High complexity & costs FY 2022/23 • 9 entities including new Akribion Genomics • Significantly improved efficiency & manageability • Lower running costs FY 2021/22 • Active portfolio management: • Weriol Gr

  7. Slide 7: Gaining financial flexibility

    Efficient & Transparent Organization gaining financial flexibility Status Quo Holding (AG) is highly loss making due to: Gaining Flexibility • Holding costs • Incubator costs • M&A costs • Minority buyouts Group Sources of financing: • Equity only at AG level • No debt capacity at AG level due to lo

  8. Slide 8: Refunding: One BioProducts creation enabling financial flexibility at AG level

    Efficient & Transparent Organization One BioProducts creation is enabling increased financial flexibility at AG level 1. BRAIN Biotech AG Buy-Out Dividend Biocatalysts Minorities Annual Refunding 2. BRAIN Biotech AG Shares Sells to Biocatalysts Cash ~91% shareholding 3. Biocatalysts Creates One BioP

  9. Slide 9: Gaining financial flexibility via strategic reorganization

    Efficient & Transparent Organization gaining financial flexibility via strategic reorganization BRAIN Biotech AG Holding  Active portfolio management  Facilitate cross-divisional synergies  Drive M&A  Equity financing for strategic considerations One BioProducts BioScience BioIncubator • Further

  10. Slide 10: Key takeaways strategic reorganization

    Efficient & Transparent Organization key takeaways strategic reorganization  Transparency: improved reporting for all stakeholders  Alignment: internal organization with external reporting  Operational business model: BRAIN Biotech as integrated solutions provider with technology USPs  Focused:

BRAIN Biotech — Investor Day (February 2023) on 6ix